DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
OXFORD, United Kingdom, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Midatech Pharma (AIM:MTPH) (Nasdaq:MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, today announced that it will present at the Biotech Showcase™ 2016 to be held January 11-13 at the Parc 55 Hotel in San Francisco.
Dr. Jim Phillips, Chief Executive Officer of Midatech Pharma, will present a company overview on Monday, January 11, 2016 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the presentation will be available to be accessed at http://edge.media-server.com/m/p/y9pmodcz or from Midatech’s website at the Media, Events section www.midatechpharma.com. An archived version of the webcast will be available for 90 days.
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech’s strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions. The Company’s R&D activities are supported by two breakthrough drug delivery technologies. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com
For more information, please contact: Midatech Pharma PLC Jim Phillips, CEO Tel: +44 (0)1235 841575 www.midatechpharma.com Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) Corporate Finance Freddy Crossley / Adam James / Atholl Tweedie / Duncan Monteith Broking Tom Salvesen Tel: +44 (0)20 7886 2500 RBC Europe Limited (Joint Broker) Darrell Uden / Paul Tomasic / Rupert Walford / Thomas Stockman Tel: +44 (0)207 653 4000 Consilium Strategic Communications (Financial PR) Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys Tel: +44 (0)20 3709 5700 Email: [email protected] RX Communications Group (US IR) Melody Carey Tel: (917) 322-2571 Email: [email protected]
